血管內沖擊波碎石術結合藥物涂層球囊治療股總動脈鈣化病變的療效觀察_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

李立強 , 高喜翔 , 佟鑄 ,  郭連瑞

首都醫科大學宣武醫院血管外科（北京 100053）;

Corresponding?author：

郭連瑞, Email: guolianrui@xwhos.org

Keywords：

股總動脈; 鈣化病變; 血管內沖擊波碎石術; 藥物涂層球囊

DOI：

10.7507/1007-9424.202604079

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的評估血管內沖擊波碎石術結合藥物涂層球囊治療股總動脈鈣化病變的安全性和有效性。方法回顧性分析2023年2月至2025年7月期間在首都醫科大學宣武醫院血管外科采用血管內沖擊波碎石術結合藥物涂層球囊進行股總動脈鈣化病變腔內治療的8例患者的臨床資料。結果手術技術成功率100%，術中均實現靶血管最終殘余狹窄率小于30%，無補救性支架植入。術后隨訪6～18個月、（12.00±3.89）個月，無主要不良肢體事件發生，無死亡及截肢；3例發生靶血管再狹窄，其中2例再干預。結論使用血管內沖擊波碎石術結合藥物涂層球囊治療股總動脈鈣化病變具有一定的安全性和有效性。

Citation： 李立強, 高喜翔, 佟鑄, 郭連瑞. 血管內沖擊波碎石術結合藥物涂層球囊治療股總動脈鈣化病變的療效觀察. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(8): 1110-1113. doi: 10.7507/1007-9424.202604079 Copy

1.	Kang JL, Patel VI, Conrad MF, et al. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy [J]. J Vasc Surg, 2008, 48(4): 872-877.
2.	Chaney M, Joshi G, Serrato JC, et al. Morbidity and mortality of common femoral endarterectomy [J]. J Vasc Surg, 2024, 80(1): 199-203.
3.	李立強, 佟鑄, 崔世軍, 等. 股總動脈內膜剝脫術后再狹窄的影響因素 [J]. 中華老年多器官疾病雜志, 2016, 21(8): 576-580.
4.	Giannakopoulos N, Tzamtzidou S, Manou D, et al. Comparative efficacy of open endarterectomy versus endovascular treatments in common femoral artery stenocclusive disease: a Bayesian hierarchical meta-analysis [J/OL]. Vascular, 2026: 17085381261426647. doi: 10.1177/17085381261426647.
5.	Okuno S, Iida O, Shiraki T, et al. Impact of calcification on clinical outcomes after endovascular therapy for superficial femoral artery disease: assessment using the peripheral artery calcification scoring system [J]. J Endovasc Ther, 2016, 23(5): 731-737.
6.	Fujihara M, Takahara M, Sasaki S, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease [J]. J Endovasc Ther, 2017, 24(3): 367-375.
7.	張帆, 成津, 武森森, 等. 血管內沖擊波碎石術治療股腘動脈重度鈣化閉塞病變的臨床效果 [J]. 血管與腔內血管外科雜志, 2024, 10(4): 395-400.
8.	Hu L, Wang H, Pan D, et al. Three-year results of combining debulking devices with drug-coated balloons for the treatment of de novo femoropopliteal arteriosclerosis obliterans [J]. Ann Vasc Surg, 2025, 114: 63-73.
9.	Ye IB, Giannopoulos S, Kokkosis AA, et al. Challenging the no-stent zone: intravascular lithotripsy for common femoral artery disease [J/OL]. J Clin Med, 2025, 14(18): 6492. doi: 10.3390/jcm14186492.
10.	Picard F, Pham V, El Harrrouchi S, et al. Drug-coated balloon strategy following intravascular lithotripsy to treat coronary de novo lesion: mid-term clinical outcomes of a preliminary experience[J/OL]. J Invasive Cardiol, 2026, 38(1). doi: 10.25270/jic/25.00183.
11.	R?s?nen A, Eranti A, Rissanen TT. Safety and feasibility of the treatment of calcified de novo coronary artery lesions with drug-coated balloon angioplasty after intravascular lithotripsy [J/OL]. Front Cardiovasc Med, 2026: 13: 1753826. doi: 10.3389/fcvm.2026.1753826.
12.	Dubosq-Lebaz M, Jacomino V, Coscas R. Advances in intravascular lithotripsy: mechanisms, devices, and clinical applications [J]. Expert Rev Med Devices, 2025, 22(3): 209-218.
13.	Kong SYZ, Jenil AA, Yong E, et al. Cracking the calcium barrier: intravascular lithotripsy for peripheral arterial disease-1-year outcomes from 50 procedures in a Singapore tertiary hospital [J/OL]. J Endovasc Ther, 2025: 15266028251399111. doi: 10.1177/15266028251399111.
14.	Brodmann M, Werner M, Brinton TJ, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions [J]. J Am Coll Cardiol, 2017, 70(7): 908-910.
15.	Brodmann M, Werner M, Holden A, et al. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD Ⅱ [J]. Catheter Cardiovasc Interv, 2019, 93(2): 335-342.
16.	Tepe G, Brodmann M, Werner M, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD Ⅲ trial [J]. JACC Cardiovasc Interv, 2021, 14(12): 1352-1361.
17.	Armstrong EJ, Adams G, Soukas PA, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the Disrupt PAD Ⅲ observational study [J]. J Endovasc Ther, 2026, 33(2): 853-862.
18.	Wong CP, Chan LP, Au DM, et al. Efficacy and safety of intravascular lithotripsy in lower extremity peripheral artery disease: a systematic review and meta-analysis [J]. Eur J Vasc Endovasc Surg, 2022, 63(3): 446-456.
19.	包俊敏, 劉冰, 沈晨陽, 等. 股腘動脈閉塞癥的診斷和治療中國專家共識 [J]. 中國循環雜志, 2026, 37(7): 669-676.
20.	Al-Nejar M, Schoonjans C, Wustenberghs K, et al. Revisiting the gold standard: supera stent performance in common femoral artery lesions, medium-to long-term results [J]. Ann Vasc Surg, 2025, 120: 302-308.

1. Kang JL, Patel VI, Conrad MF, et al. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy [J]. J Vasc Surg, 2008, 48(4): 872-877.
2. Chaney M, Joshi G, Serrato JC, et al. Morbidity and mortality of common femoral endarterectomy [J]. J Vasc Surg, 2024, 80(1): 199-203.
3. 李立強, 佟鑄, 崔世軍, 等. 股總動脈內膜剝脫術后再狹窄的影響因素 [J]. 中華老年多器官疾病雜志, 2016, 21(8): 576-580.
4. Giannakopoulos N, Tzamtzidou S, Manou D, et al. Comparative efficacy of open endarterectomy versus endovascular treatments in common femoral artery stenocclusive disease: a Bayesian hierarchical meta-analysis [J/OL]. Vascular, 2026: 17085381261426647. doi: 10.1177/17085381261426647.
5. Okuno S, Iida O, Shiraki T, et al. Impact of calcification on clinical outcomes after endovascular therapy for superficial femoral artery disease: assessment using the peripheral artery calcification scoring system [J]. J Endovasc Ther, 2016, 23(5): 731-737.
6. Fujihara M, Takahara M, Sasaki S, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease [J]. J Endovasc Ther, 2017, 24(3): 367-375.
7. 張帆, 成津, 武森森, 等. 血管內沖擊波碎石術治療股腘動脈重度鈣化閉塞病變的臨床效果 [J]. 血管與腔內血管外科雜志, 2024, 10(4): 395-400.
8. Hu L, Wang H, Pan D, et al. Three-year results of combining debulking devices with drug-coated balloons for the treatment of de novo femoropopliteal arteriosclerosis obliterans [J]. Ann Vasc Surg, 2025, 114: 63-73.
9. Ye IB, Giannopoulos S, Kokkosis AA, et al. Challenging the no-stent zone: intravascular lithotripsy for common femoral artery disease [J/OL]. J Clin Med, 2025, 14(18): 6492. doi: 10.3390/jcm14186492.
10. Picard F, Pham V, El Harrrouchi S, et al. Drug-coated balloon strategy following intravascular lithotripsy to treat coronary de novo lesion: mid-term clinical outcomes of a preliminary experience[J/OL]. J Invasive Cardiol, 2026, 38(1). doi: 10.25270/jic/25.00183.
11. R?s?nen A, Eranti A, Rissanen TT. Safety and feasibility of the treatment of calcified de novo coronary artery lesions with drug-coated balloon angioplasty after intravascular lithotripsy [J/OL]. Front Cardiovasc Med, 2026: 13: 1753826. doi: 10.3389/fcvm.2026.1753826.
12. Dubosq-Lebaz M, Jacomino V, Coscas R. Advances in intravascular lithotripsy: mechanisms, devices, and clinical applications [J]. Expert Rev Med Devices, 2025, 22(3): 209-218.
13. Kong SYZ, Jenil AA, Yong E, et al. Cracking the calcium barrier: intravascular lithotripsy for peripheral arterial disease-1-year outcomes from 50 procedures in a Singapore tertiary hospital [J/OL]. J Endovasc Ther, 2025: 15266028251399111. doi: 10.1177/15266028251399111.
14. Brodmann M, Werner M, Brinton TJ, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions [J]. J Am Coll Cardiol, 2017, 70(7): 908-910.
15. Brodmann M, Werner M, Holden A, et al. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD Ⅱ [J]. Catheter Cardiovasc Interv, 2019, 93(2): 335-342.
16. Tepe G, Brodmann M, Werner M, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD Ⅲ trial [J]. JACC Cardiovasc Interv, 2021, 14(12): 1352-1361.
17. Armstrong EJ, Adams G, Soukas PA, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the Disrupt PAD Ⅲ observational study [J]. J Endovasc Ther, 2026, 33(2): 853-862.
18. Wong CP, Chan LP, Au DM, et al. Efficacy and safety of intravascular lithotripsy in lower extremity peripheral artery disease: a systematic review and meta-analysis [J]. Eur J Vasc Endovasc Surg, 2022, 63(3): 446-456.
19. 包俊敏, 劉冰, 沈晨陽, 等. 股腘動脈閉塞癥的診斷和治療中國專家共識 [J]. 中國循環雜志, 2026, 37(7): 669-676.
20. Al-Nejar M, Schoonjans C, Wustenberghs K, et al. Revisiting the gold standard: supera stent performance in common femoral artery lesions, medium-to long-term results [J]. Ann Vasc Surg, 2025, 120: 302-308.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

血管內沖擊波碎石術結合藥物涂層球囊治療股總動脈鈣化病變的療效觀察

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content